CHIMERISM SPLIT CELL ANALYSIS – B CELL CD19 Test
Test Name: CHIMERISM SPLIT CELL ANALYSIS – B CELL CD19 Test
Components: Price 1870.0 AED
Sample Condition: 4 ml (2 ml min.) whole blood / Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Indicate Date of Bone Marrow Transplant; date/Lab number of Pre transplant sample of patient & donor for chimerism registered under code N057.
Report Delivery: Sample Daily by 11 am; Report 7 Working days
Method: PCR, STR / Fragment Analysis
Test type: Bone Marrow Transplantation
Doctor: Hematologist, Oncologist
Test Department:
Pre Test Information: Indicate Date of Bone Marrow Transplant; date/Lab number of Pre transplant sample of patient & donor for chimerism registered under code N057.
Test Details: Chimerism split cell analysis is a laboratory test used to determine the presence and proportion of different cell populations in an individual’s body. This test is commonly used in stem cell and organ transplant patients to assess the success of the transplantation process. In the context of B cell chimerism, the test specifically analyzes the proportion of B cells expressing the CD19 marker. CD19 is a protein found on the surface of B cells, which play a crucial role in the immune response. The chimerism split cell analysis – B cell (CD19) test involves separating the patient’s blood or bone marrow sample into individual cells. These cells are then stained with fluorescent markers specific to CD19, allowing for the identification and quantification of B cells expressing this marker. By comparing the proportion of CD19-positive B cells to the total B cell population, the test can determine the level of chimerism or the presence of different cell populations in the patient. This information is valuable in assessing the success of a stem cell or organ transplant, as well as monitoring for potential complications such as graft rejection or relapse of the underlying condition. Overall, the chimerism split cell analysis – B cell (CD19) test provides valuable insights into the immune reconstitution and engraftment process, helping clinicians make informed decisions regarding patient care and treatment.
Test Name | CHIMERISM SPLIT CELL ANALYSIS – B CELL CD19 Test |
---|---|
Components | |
Price | 1870.0 AED |
Sample Condition | 4 ml (2 ml min.) whole blood \/ Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Indicate Date of Bone Marrow Transplant;date\/Lab number of Pre transplant sample of patient & donor for chimerism registered under code N057. |
Report Delivery | Sample Daily by 11 am; Report 7 Working days |
Method | PCR, STR / Fragment Analysis |
Test type | Bone Marrow Transplantation |
Doctor | Hematologist, Oncologist |
Test Department: | |
Pre Test Information | Indicate Date of Bone Marrow Transplant;date/Lab number of Pre transplant sample of patient & donor for chimerism registered under code N057. |
Test Details |
Chimerism split cell analysis is a laboratory test used to determine the presence and proportion of different cell populations in an individual’s body. This test is commonly used in stem cell and organ transplant patients to assess the success of the transplantation process. In the context of B cell chimerism, the test specifically analyzes the proportion of B cells expressing the CD19 marker. CD19 is a protein found on the surface of B cells, which play a crucial role in the immune response. The chimerism split cell analysis – B cell (CD19) test involves separating the patient’s blood or bone marrow sample into individual cells. These cells are then stained with fluorescent markers specific to CD19, allowing for the identification and quantification of B cells expressing this marker. By comparing the proportion of CD19-positive B cells to the total B cell population, the test can determine the level of chimerism or the presence of different cell populations in the patient. This information is valuable in assessing the success of a stem cell or organ transplant, as well as monitoring for potential complications such as graft rejection or relapse of the underlying condition. Overall, the chimerism split cell analysis – B cell (CD19) test provides valuable insights into the immune reconstitution and engraftment process, helping clinicians make informed decisions regarding patient care and treatment. |